Early Subtypes and Progressions of Progressive Supranuclear Palsy: A Data-Driven Brain Bank Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Progressive supranuclear palsy (PSP) is typically characterized by vertical supranuclear gaze palsy and early falls, referred to as Richardson’s syndrome (PSP-RS). Other presentations include postural instability (PSP-PI), parkinsonism (PSP-P), speech/language impairment (PSP-SL), frontal presentation (PSP-F), ocular motor dysfunction (PSP-OM), and corticobasal syndrome (PSP-CBS). Differences across the early presentations and in their subsequent progression have yet to be elucidated.
Objective
This study aimed to characterize early PSP subtypes and their subsequent progressions using a large postmortem dataset.
Methods
An automated pipeline incorporating fine-tuned ChatGPT models was developed. The pipeline collected 195 clinical features with onset information from autopsy-confirmed PSP cases without significant neurodegenerative co-pathologies.
Results
A structured clinicopathologic dataset from 588 patients was analyzed. After distilling results with unsupervised clustering, a decision tree model was developed. With five clinical manifestations: frontal presentation, PI, OM, SL, and parkinsonism, this mutually exclusive algorithm identified seven subtypes: PSP-PF (postural and frontal dysfunction), PSP-RS, PSP-PI, PSP-P, PSP-SL, PSP-F, and PSP-OM. PSP-PF, defined by PI and frontal presentation, showed rapid progression, the shortest median disease duration (six years), and high tau burden in cortical and subcortical regions. In PSP-F, frontal presentation preceded other symptoms by four years, and the disease duration was the second longest (nine years) after PSP-P (10 years). PSP-CBS was not identified as an independent subtype.
Conclusions
This data-driven study identified a novel, aggressive PSP phenotype characterized by early postural and frontal dysfunction. Early subtyping utilizing the decision tree would help clinicians estimate progression and facilitate early patient recruitment for clinical trials.
